- Home
- EDF vs CBIO Comparison
EDF vs CBIO Comparison
Compare EDF & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDF
- CBIO
- Stock Information
- Founded
- EDF 2010
- CBIO 2003
- Country
- EDF United States
- CBIO United States
- Employees
- EDF N/A
- CBIO N/A
- Industry
- EDF Investment Managers
- CBIO
- Sector
- EDF Finance
- CBIO
- Exchange
- EDF Nasdaq
- CBIO Nasdaq
- Market Cap
- EDF 160.2M
- CBIO 173.5M
- IPO Year
- EDF N/A
- CBIO N/A
- Fundamental
- Price
- EDF $5.08
- CBIO $13.00
- Analyst Decision
- EDF
- CBIO Strong Buy
- Analyst Count
- EDF 0
- CBIO 5
- Target Price
- EDF N/A
- CBIO $25.60
- AVG Volume (30 Days)
- EDF 160.6K
- CBIO 90.6K
- Earning Date
- EDF 01-01-0001
- CBIO 07-31-2025
- Dividend Yield
- EDF 13.14%
- CBIO N/A
- EPS Growth
- EDF N/A
- CBIO N/A
- EPS
- EDF N/A
- CBIO N/A
- Revenue
- EDF N/A
- CBIO N/A
- Revenue This Year
- EDF N/A
- CBIO N/A
- Revenue Next Year
- EDF N/A
- CBIO N/A
- P/E Ratio
- EDF N/A
- CBIO N/A
- Revenue Growth
- EDF N/A
- CBIO N/A
- 52 Week Low
- EDF $3.51
- CBIO $10.83
- 52 Week High
- EDF $5.50
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- EDF 45.91
- CBIO 47.87
- Support Level
- EDF $4.97
- CBIO $12.03
- Resistance Level
- EDF $5.09
- CBIO $13.21
- Average True Range (ATR)
- EDF 0.06
- CBIO 0.85
- MACD
- EDF -0.01
- CBIO -0.07
- Stochastic Oscillator
- EDF 41.30
- CBIO 36.72
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.